Research information only, not medical advice. In clinical trials, MK-677's reported side effects were increased appetite, transient rises in blood glucose with reduced insulin sensitivity, and fluid retention or oedema. It is investigational, and its long-term safety has not been established.
MK-677 (ibutamoren) is an investigational oral ghrelin-receptor agonist that raises growth hormone and IGF-1; it is not approved by the FDA. In a one-year randomised, double-blind, placebo-controlled trial in healthy older adults (Nass et al., 2008), the reported adverse effects were increased appetite, transient increases in blood glucose with reduced insulin sensitivity, and fluid retention or oedema, and the authors noted that long-term safety has not been established. This is trial data for an investigational compound, reported as evidence, not medical advice.
For the full evidence base, clinical trials, and regulatory status, see the Ibutamoren research overview . Related: mk-677 before and after .
Sources
Frequently asked questions
- What are the side effects of MK-677?
- Reported in trials: increased appetite, transient rises in blood glucose with lower insulin sensitivity, and fluid retention or oedema. Long-term safety is not established.
- Does MK-677 raise blood sugar?
- In the one-year trial, MK-677 caused transient increases in blood glucose and reduced insulin sensitivity. This is trial data, not medical advice.
Updated · sourced to primary documents